Quan Capital — Full Portfolio
30 tracked investments · listed companies and verified rows first
Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer.
BiotechHealthtechMenlo Park, US
Aya Jakobovits(Executive Officer, Director)Nathan Hubbard(Executive Officer)inChen Schor(President, Chief Executive Officer and Director)in
BoardJonathan Silverstein(Director)inCarl Gordon(Director)inFlorent Gros(Director)
Co-investorsForesite CapitalOrbiMedPontifax Venture CapitalaMoonNovartis Venture FundPureTech Health
Design Therapeutics is a biopharmaceutical company developing small molecule therapeutic candidates for serious genetic diseases through its GeneTAC (Gene Targeted Chimera) platform.
BiotechMedical DevicesSolana Beach, US
Pratik Shah, Ph.D.(Executive Officer, Director)Aseem Z. Ansari, Ph.D.(Director)Sean Jeffries, Ph.D.(Executive Officer)
BoardSimeon George, M.D.(Director)Stella Xu, Ph.D.(Director)Rodney Lappe, Ph.D.(Director)
Co-investorsAvoro Capital AdvisorsRA CapitalSR One Capital ManagementWestRiver GroupQuan Venture
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
BiotechBeltsville, US
Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)inUdayan Guha(Executive Officer)inSteven P. Cobourn(Executive Officer)inSourav Kundu(Executive Officer)inKevin Shaw(Executive Officer)in
Co-investorsBay City CapitalCanaan PartnersLAVLilly Asia VenturesPfizer Venture InvestmentsSofinnova Ventures+4 more
Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor.
BiotechHealthtechWaltham, US
LEON O. MOULDER, JR.(Director)Lonnie Moulder(Founder, CEO & Chairman)JOSEPH FARMER(Executive Officer)HUA MU(Executive Officer, Director)in
BoardPATRICK GERALD ENRIGHT(Director)inHONGBO LU(Director)
Co-investorsDelos CapitalLongitude CapitalNew Enterprise Associates (NEA)Norwest Venture PartnersSR One Capital ManagementVivo Capital+1 more
Crescendo Biologics develops novel immune cell-enhancing therapeutics for immuno-oncology using its patent-protected Humabody VH platform, a fully human domain technology clinically validated in oncology and immunology.
BiotechHealthtechMedical Devices
Co-investorsAndera PartnersSofinnova PartnersAstellas Venture Management LLCEMBL VenturesFuture Planet CapitalAvlar BioVentures+1 more
Adcentrx Therapeutics is a biotech company focused on the discovery and clinical development of antibody-drug conjugates (ADCs) for oncology.
BiotechHealthtech
Hui Li(Founder, President & CEO)in
Co-investorsEight Roads VenturesF-Prime CapitalDelta Capital
An innovative biopharmaceutical company focused on developing therapies for chronic kidney disease across multiple clinical stages, with a pipeline of eight products covering conditions such as hyperphosphatemia, renal anemia, IgA nephropathy, and diabetic kidney disease.
BiotechDigital HealthHealthtechMedical DevicesShanghai, CN
Co-investorsLAVLilly Asia Ventures3E Bioventures Capital3H Health InvestmentSherpa Healthcare PartnersYuanBio Venture Capital
Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer.
BiotechHealthtechGaithersburg, US
Han Lee(Executive Officer)Rami Elghandour(Executive Officer, Director)in
BoardJill Carroll(Director)inAli Behbahani(Director)inDerek Yoon(Director)inTiba Aynechi(Director)in
Co-investorsLG Technology VenturesNew Enterprise Associates (NEA)Samsara BioCapitalSixty Degree CapitalSolasta VenturesSR One Capital Management+5 more
Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.
Biotech
Athena Countouriotis(Co-Founder, Chief Executive Officer)
Co-investorsDelos CapitalForesite CapitalINCE CapitalLongwood FundNew Enterprise Associates (NEA)OrbiMed+3 more
Centrexion develops therapies for the treatment of pain, focusing on the design and execution of clinical trials for pain drug development.
BiotechHealthtechBaltimore, US
James N. Campbell(President, Chief Scientific Officer)inKerrie L. Brady(Executive Officer)inGregg Beloff(Executive Officer)Jeffrey B. Kindler(Chief Executive Officer)inCharles Oh(Chief Medical Officer)inSmital Shah(Acting CBO)in
Co-investorsCatalio Capital Management, LPEFung CapitalNew Enterprise Associates (NEA)6 Dimensions CapitalExome Asset Management
Caidya is a global full-service clinical research organization (CRO) that supports biopharmaceutical companies with clinical trial design, execution, and patient recruitment across more than 40 countries.
BiotechDigital HealthHealthtech
Co-investorsQiming Venture Partners
iCarbonX (碳云智能) develops multi-omics testing and AI-based technologies — including ctDNA detection, silicon-based biochips, TCR peptide chips, and AI drug design — to support cancer neoantigen research, clinical diagnostics, new drug development, and health management.
AI & Machine LearningBiotechDigital Health
Co-investorsThird Point Ventures
Kira Pharmaceuticals is a biotech company developing therapies targeting complement biology to treat complement-mediated diseases.
BiotechHealthtechCambridge, US
Wenru Song(Founder)in
Co-investorsForesite CapitalVivo CapitalIkarian Capital
Oricell Therapeutics (原启生物) is a clinical-stage biopharmaceutical company developing cell therapies, including CAR-T products targeting GPRC5D for relapsed/refractory multiple myeloma and GPC3 for advanced liver cancer.
BiotechDeep TechHealthtechShanghai, CN
Helen Yang(Founder)in
Co-investorsQiming Venture PartnersVivo CapitalRTW Investments L.P.
Pinnacle Medicines develops oral peptide-based therapies designed to deliver antibody-like efficacy in pill form for patients with chronic diseases.
BiotechDigital HealthDoylestown, US
Chengzao Sun(Founder)inSandeep Somani(Founder)in
Co-investorsForesite CapitalRA CapitalLAVOrbiMed
Sail Biomedicines develops RNA-based medicines using a platform integrating Endless RNA and targeted nanoparticle delivery technology.
AI & Machine LearningBiotechDeep TechCambridge, US
John Mendlein(Executive Chairman)
Co-investorsFlagship PioneeringNextech Invest
Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.
Co-investorsAisling CapitalARCH Venture PartnersFlagship VenturesREDMILE
Tempest Therapeutics is a clinical-stage biotechnology company developing in vivo CAR-T cell therapies for autoimmune and oncology indications.
BiotechHealthtechBrisbane, US
Stephen Brady(Director)inMatthew Angel(Executive Officer, Director)Nicholas Maestas(Executive Officer)inThomas W. Dubensky, Jr.(Executive Officer, Director)Thomas Woiwode(Director)Geoffrey Nichol(Director)
Co-investorsF-Prime CapitalLAVLilly Asia VenturesNew Enterprise Associates (NEA)Roche Venture FundVersant Ventures
Therorna develops circular RNA-based therapeutic candidates and preventive medicines for diseases with unmet clinical needs.
AI & Machine LearningBiotechDeep TechHealthtechBeijing, CN
Co-investorsCenova Capital3H Health InvestmentMSA CapitalSherpa Healthcare Partners
Windward delivers AI-powered operational intelligence for maritime security and commercial applications, fusing behavioral analytics and multi-sensor data to detect threats and opportunities.
AI & Machine LearningData & InfrastructureDefense TechTel Aviv
Amiad Daniel(Executive Officer, Director)Matan Peled(Director)in
BoardDov Gatmon(Director)Patrick Poon(Director)Eden Shochat(Director)inThompson Hutton(Director)in
Co-investorsAlephFTV CapitalThompson Hutton, LLCJanus Henderson InvestorsPivotal Life SciencesQiming Venture Partners+3 more
Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases.
BiotechHealthtech
Co-investorsOrbiMedRA CapitalSanofi VenturesSR One Capital ManagementJanus Henderson InvestorsNovo Holdings+3 more
Zidan Medical develops an endobronchial radiofrequency ablation system, using a small flexible RF catheter with "virtual electrode" forward-throw technology to deliver targeted, temperature-controlled energy to destroy lung lesions.
HardwareHealthtechMedical DevicesCupertino, US
Don Tanaka(VP of Clinical Research)inShashank Raina(VP of R&D)in
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
ArmobioEluminexbioInterius BioTherapeuticsMedxtmcOriCellRareStone GroupSilexonvisit www.interiusbio.com
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.